EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Soloxolone N-3-(Dimethylamino)propylamide Suppresses Tumor Growth and Mitigates Doxorubicin-Induced Hepatotoxicity in RLS40 Lymphosarcoma-Bearing Mice

Arseny D Moralev iD, Aleksandra V Sen'kova iD, Alina A Firsova, Daria E Solomina, Artem D Rogachev iD, Oksana V Salomatina, Nariman F Salakhutdinov, Marina A Zenkova iD, Andrey V Markov iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262411912 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Arseny D Moralev und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrent'ev Ave., 8, 630090 Novosibirsk, R…. Hauptthemen laut MEDLINE: Doxorubicin, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, Russian state-funded project for ICBFM SB RAS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug resistance (MDR) remains a significant obstacle to effective cancer chemotherapy, primarily due to overexpression of P-glycoprotein (P-gp), which reduces intracellular accumulation of cytotoxic drugs. This study evaluated the pharmacological potential of the glycyrrhetinic acid derivative soloxolone N-3-(dimethylamino)propylamide (Sol-DMAP) as a biocompatible P-gp inhibitor with hepatoprotective properties. Using a murine model of P-gp-overexpressing RLS40 lymphosarcoma, we demonstrated that Sol-DMAP significantly enhanced the antitumor efficacy of doxorubicin (DOX) by increasing its intratumoral concentration 4.7-fold without enhancing systemic toxicity. Independently, Sol-DMAP exhibited direct antitumor activity, reducing tumor growth in vivo and inducing apoptosis and G1-phase arrest in RLS40 cells in vitro. In addition, Sol-DMAP mitigated DOX-induced hepatic injury by reducing necrotic and dystrophic changes in liver tissue and restoring heme oxygenase 1 (Hmox1) expression. Further studies in HepG2 cells confirmed that Sol-DMAP activated the NRF2-dependent antioxidant response, upregulating HMOX1, GCLC, GCLM, and NQO1 genes. Molecular docking revealed that Sol-DMAP can disrupt the KEAP1-NRF2 interaction, likely leading to NRF2 activation. Collectively, these findings demonstrate that Sol-DMAP effectively reverses P-gp-mediated MDR while protecting the liver from oxidative stress, highlighting its potential as a multifunctional scaffold for the development of safer and more effective chemotherapeutic adjuvants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinChemical and Drug Induced Liver InjuryAnimalsMiceHumansNF-E2-Related Factor 2ApoptosisHep G2 CellsHeme Oxygenase-1Cell Line, TumorATP Binding Cassette Transporter, Subfamily B, Member 1Antineoplastic AgentsDrug Resistance, NeoplasmMaleLiverXenograft Model Antitumor AssaysCell Proliferation

Stichwörter der Autor:innen

NRF2 signalingP-glycoproteindoxorubicinglycyrrhetinic acidhepatoprotectionlymphosarcomamultidrug resistanceoxidative stresssoloxolone

Substanzen

DoxorubicinNF-E2-Related Factor 2Heme Oxygenase-1ATP Binding Cassette Transporter, Subfamily B, Member 1Antineoplastic Agents

Autor:innen und Institutionen

  • Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrent'ev Ave., 8, 630090 Novosibirsk, Russia.
  • Faculty of Natural Sciences, Novosibirsk State University, Pirogov St. 2, 630090 Novosibirsk, Russia.
  • N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrent'ev Ave., 9, 630090 Novosibirsk, Russia.

ORCID-Profile: Arseny D Moralev, Aleksandra V Sen'kova, Artem D Rogachev, Marina A Zenkova, Andrey V Markov

Förderung

  • Russian Science Foundation
  • Russian state-funded project for ICBFM SB RAS

Zitieren

APA

Moralev, A. D., Sen'kova, A. V., Firsova, A. A., Solomina, D. E., Rogachev, A. D., Salomatina, O. V., Salakhutdinov, N. F., Zenkova, M. A., & Markov, A. V. (2025). Soloxolone N-3-(Dimethylamino)propylamide Suppresses Tumor Growth and Mitigates Doxorubicin-Induced Hepatotoxicity in RLS40 Lymphosarcoma-Bearing Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262411912

Vancouver

Moralev AD, Sen'kova AV, Firsova AA, Solomina DE, Rogachev AD, Salomatina OV, et al. Soloxolone N-3-(Dimethylamino)propylamide Suppresses Tumor Growth and Mitigates Doxorubicin-Induced Hepatotoxicity in RLS40 Lymphosarcoma-Bearing Mice. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262411912

BibTeX
@article{Moralev2025,
  author = {Moralev, Arseny D and Sen'kova, Aleksandra V and Firsova, Alina A and Solomina, Daria E and Rogachev, Artem D and Salomatina, Oksana V and Salakhutdinov, Nariman F and Zenkova, Marina A and Markov, Andrey V},
  title = {Soloxolone N-3-(Dimethylamino)propylamide Suppresses Tumor Growth and Mitigates Doxorubicin-Induced Hepatotoxicity in RLS40 Lymphosarcoma-Bearing Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262411912}
}
Kostenlos starten →